Omniscan (Gadodiamide)

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve the visualization of various anatomical regions and disease processes.

• Central nervous system imaging: improves the detection of lesions, tumors, and vascular malformations.
• Cardiovascular imaging: enhances visualization of cardiac chambers, vessels, and myocardial perfusion.
• Abdominal and pelvic imaging: clarifies organ structure and helps identify lesions in liver, kidneys, and other viscera.
• Whole‑body screening: aids in the detection of metastatic disease and systemic pathology.
• Vascular angiography: provides high‑resolution images of arteries and veins for interventional planning.

• Gadodiamide is a low‑molecular‑weight, non‑ionic gadolinium chelate that distributes rapidly in the extracellular fluid after intravenous injection. Its paramagnetic gadolinium ion shortens T1 relaxation times of nearby water protons, producing increased signal intensity on T1‑weighted MRI sequences and thereby enhancing the contrast between normal and pathological tissues.

Adverse reactions to gadodiamide‑based contrast agents are generally uncommon but can range from mild to severe.

Common Side Effects

• Nausea: mild, transient episodes reported by some patients.
• Headache: occasional brief discomfort following injection.
• Injection site discomfort: mild pain or erythema at the site of administration.
• Warmth or flushing: transient sensation during or shortly after injection.
• Metallic taste: brief metallic sensation in the mouth.

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment.
• Anaphylactoid reactions: hives, bronchospasm, or hypotension requiring emergency care.
• Severe allergic reaction: angio‑edema or anaphylaxis.
• Cardiac arrest: extremely rare but reported in hypersensitive individuals.
• Renal toxicity: worsening kidney function in susceptible patients.

When using Omniscan, clinicians should assess patient history and renal function, and follow recommended safety measures.

• Renal assessment: evaluate glomerular filtration rate before administration.
• Hydration: ensure adequate patient hydration to facilitate gadolinium elimination.
• Allergy history: screen for prior reactions to contrast media.
• Pregnancy: avoid use unless clearly needed, as fetal safety data are limited.
• Pediatric use: adjust dosing according to weight and monitor closely.
• Store at ambient temperature: keep in original packaging, protect from light and moisture.

Omniscan may interact with other agents that affect renal function or provoke hypersensitivity.

Major Interactions (Avoid)

• Nephrotoxic drugs: concurrent use with high‑dose aminoglycosides or IV contrast iodine may increase renal risk.
• Immunosuppressants: heightened risk of severe allergic reactions when combined with biologic agents.

Moderate Interactions (Monitor Closely)

• Diuretics: may alter renal clearance of gadodiamide, requiring monitoring of kidney function.
• Metformin: assess renal function and consider temporary discontinuation to prevent lactic acidosis.
• ACE inhibitors/ARBs: monitor for additive effects on renal perfusion.
• NSAIDs: may compound renal stress, especially in patients with pre‑existing kidney disease.
• Calcium channel blockers: no direct interaction but monitor blood pressure changes during imaging procedures.